Brought to you by 
Sarepta nets $477.5mm via FOPO
12 Nov 2018
Executive Summary
Rare disease-focused Sarepta Therapeutics Inc. netted $477.5mm through the follow-on public offering of 3.8mm common shares at $131 each. The company will use the proceeds for R&D and manufacturing activities and to finance capital expenditures and capacity expansions.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com